Cardiotoxic side-effects of doxorubicin limit the clinical use of this anti-cancer agent. Iron
chelators have been studied as protectors against doxorubicin-induced cardiotoxicity. These …

Doxorubicin is a widely used anthracycline anticancer agent. Its use may cause
cardiomyopathy: in fact, the development of cumulative dose-related cardiotoxicity forms the …

Anthracycline antibiotics (eg doxorubicin and daunorubicin) are among the most effective
and widely used anticancer drugs. Unfortunately, their clinical use is limited by the dose …

Doxorubicin (Dox)-induced cardiotoxicity (DIC) remains a serious health burden, especially
in developing countries. Unfortunately, the high cost of current preventative strategies has …

Abstract The flavonoid 7-monohydroxyethylrutoside (monoHER) can protect against
doxorubicin-induced cardiotoxicity. A drawback of monoHER therapy would be the relatively …

Anthracycline antibiotics are among the most effective and widely used antineoplastic drugs.
Their usefulness is limited by a cumulative dose-related cardiotoxicity, whose precise …

Cancer therapy with the anthracycline doxorubicin (Dox) is limited by cardiomyopathy, which
develops in animals and patients after cumulative dosing. Generation of free radicals by Dox …

The use of anthracycline anticancer drugs is limited by a cumulative, dose-dependent
cardiac toxicity. Iron chelation has long been considered as a promising strategy to limit this …

Doxorubicin is a widely used and promising anticancer drug; however, a severe dose-
dependent cardiotoxicity hampers its therapeutic value. Doxorubicin may cause acute and …

The improvement of drugs and protocols of chemotherapeutic treatment has led to improved
outcomes and survival in patients with cancer. But along with this, at first glance a positive …